The Claim
In obese adults, one month of trimetazidine treatment has no significant effect on whole-body fat oxidation, glucose oxidation, adipose tissue mass, or adipokine levels, indicating that any metabolic effects of trimetazidine are confined to skeletal muscle and do not extend systemically.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults, taking trimetazidine for one month does not change fat burning, glucose use, fat tissue amount, or adipokine levels in the body, meaning the drug's metabolic effects are limited to skeletal muscle and do not affect the rest of the body.
See the scientific wording
In obese adults, trimetazidine does not significantly alter whole-body fat or glucose oxidation, adipose tissue mass, or adipokine levels after one month of treatment, suggesting its metabolic effects are localized to skeletal muscle and not systemic.
Trimetazidine blocks a key enzyme in muscle that breaks down fat for energy, causing fat to be stored as inert lipids instead. This reduces harmful fat buildup inside muscle cells and slightly increases sugar use, but does not change fat loss, hormone levels, or how the whole body burns fuel.
What the research says
1 studyThe drug trimetazidine changed how muscle uses fat and sugar, but didn’t make people lose body fat or change fat-related hormones. So it only works in muscles, not the whole body.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.